Provided by Tiger Fintech (Singapore) Pte. Ltd.

Beyondspring Inc

1.57
-0.0300-1.87%
Post-market: 1.56-0.0100-0.64%17:34 EDT
Volume:8.15K
Turnover:12.75K
Market Cap:63.30M
PE:-5.61
High:1.60
Open:1.57
Low:1.50
Close:1.60
Loading ...

BeyondSpring reports FY24 EPS (21c) vs. (34c) last year

TIPRANKS
·
27 Mar

BeyondSpring Files 2024 Annual Report on Form 10-K

GlobeNewswire
·
27 Mar

Beyondspring FY Cash & Investments USD 2.9 Million

THOMSON REUTERS
·
27 Mar

Press Release: BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones

Dow Jones
·
27 Mar

Beyondspring Announces $35.4 Million Sale of a Portion of Equity Interest in Seed Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies

THOMSON REUTERS
·
28 Jan

Seed Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset Rbm39 Degrader and Enters Strategic Transactions With New Investors

THOMSON REUTERS
·
28 Jan

Seed Therapeutics- Expects Ind Filing for St-01156 in First Half of 2025

THOMSON REUTERS
·
28 Jan

BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies

GlobeNewswire
·
28 Jan

SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors

GlobeNewswire
·
28 Jan

Beyondspring Presents Updated Efficacy Results From a Phase 2 Iit Study of Triple IO Combo of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic Nsclc After Progressing on Prior Immune Checkpoint Inhibitors at the 39TH SITC Annual Meeting

THOMSON REUTERS
·
11 Nov 2024

BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting

GlobeNewswire
·
11 Nov 2024